Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.

@article{Kitagawa2006DifferentMC,
  title={Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.},
  author={Nagako Kitagawa and Yutaka Yano and Esteban C Gabazza and Nelson E. Bruno and Rika Araki and Kazutaka Matsumoto and Akira Katsuki and Yasuko Hori and Kaname Nakatani and Osamu Taguchi and Yasuhiro Sumida and Koji A. O. Suzuki and Yukihiko Adachi},
  journal={Diabetes research and clinical practice},
  year={2006},
  volume={73 2},
  pages={
          150-7
        }
}
We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in non-obese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 non-obese type 2 diabetic patients and 31 normal subjects. The intra-abdominal visceral and subcutaneous fat areas were measured by computed tomography (CT). The degree of insulin resistance was evaluated by the… CONTINUE READING
BETA